2 terminated, 1 completed. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 2, Completed 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow NUC-3373: new trials by email Literature Review of NUC-3373 trials Research Report on NUC-3373
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer Fosifloxuridine Nafalbenamide, Leucovorin, Irinotecan - Colorectal Cancer, Colorectal Neoplasms | Phase 2 | Terminated | NuCana plc | 180 | 2023-04-18 | 2025-09-12 |
| NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | NuCana plc | 19 | 2023-03-08 | 2026-07-23 |
| A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment NUC-3373 + leucovorin, NUC-3373, NUFOX - Colorectal Cancer, Colorectal Neoplasms | Phase 1 / Phase 2 | Completed | NuCana plc | 111 | 2018-10-05 | 2025-04-23 |
Colonic Neoplasms (2) · Colorectal Neoplasms (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Melanoma (1) · Mesothelioma, Malignant (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1) · Triple Negative Breast Neoplasms (1)
NuCana plc (3)
United Kingdom (3) · France (2) · United States (2) · Germany (1) · Italy (1) · Spain (1)
Elisabeth Oelmann, MD PhD (1) · Elisabeth Oelmann, MD, PhD (1)
2017 (1)